RxDoctor Payments Data

Donald Mazzulla, MD

Retina Specialist · New Orleans, LANPI 1740443522

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $177,902 of the $215,067 with a category attached, or 82.7%. 18 manufacturers reported payments, led by Alimera Sciences, Inc. at 35.4% of the total. Reporting peaked in 2024 at $53,579 and has fallen 56.4% since, to $23,376 in 2025. Among retina specialist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$215,067in general payments, 2019–2025

Across 319 payments — averaging $674.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$76K
  • AbbVie$69K
  • Apellis Pharmaceuticals, Inc.$52K
  • ANI Pharmaceuticals, Inc.$10K
  • Regeneron Healthcare Solutions, Inc.$4K
  • Alcon$928
  • plus $3K from 12 others
$5,235in research payments, 2019–2025

Across 1 payment — averaging $5235.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$5K

What the payments were for

  • Consulting fees$6,5633%
  • Speaking & faculty fees$177,90283%
  • Travel & lodging$19,6199%
  • Food & beverage$10,9835%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$215,067 in reported general payments places this provider in the 95th percentile of 30 retina specialist providers in Louisiana.

See all retina specialist providers in Louisiana

Medicare billing

Part B allowed, 2024
$149,733
Medicare patients
347
Services billed
2,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate73$5,199
Atropine Sulfate28$1,804
Brimonidine Tartrate56$1,323
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat85$1,205
Ketorolac Tromethamine22$706
Dorzolamide Hcl20$529
Acetazolamide ErAcetazolamide13$452
Latanoprost26$249
Timolol Maleate26$183
Ondansetron Hcl69$177
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen63$134

Paid to pharmacies, not to this prescriber.

Other retina specialist in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →